Relationship of the reduced folate carrier gene polymorphism G80A to methotrexate plasma concentration, toxicity, and disease outcome in childhood acute lymphoblastic leukemia

Leuk Lymphoma. 2010 Apr;51(4):724-6. doi: 10.3109/10428191003611402.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Drug-Related Side Effects and Adverse Reactions / genetics
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Male
  • Membrane Transport Proteins / genetics*
  • Methotrexate / administration & dosage
  • Methotrexate / adverse effects*
  • Methotrexate / blood*
  • Osmolar Concentration
  • Polymorphism, Single Nucleotide* / physiology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Prognosis
  • Reduced Folate Carrier Protein
  • Treatment Outcome
  • Young Adult

Substances

  • Membrane Transport Proteins
  • Reduced Folate Carrier Protein
  • SLC19A1 protein, human
  • Methotrexate